Show simple item record

Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission

dc.contributor.authorKvist, Beate Charlotte Fagerlund
dc.contributor.authorChudasama, Kishan Kumar
dc.contributor.authorBrurberg, Kjetil Gundro
dc.contributor.authorRobberstad, Bjarne
dc.contributor.authorRose, Christopher James
dc.contributor.authorJuvet, Lene Kristine
dc.contributor.authorFretheim, Atle
dc.date.accessioned2022-02-21T07:15:21Z
dc.date.available2022-02-21T07:15:21Z
dc.date.created2022-02-18T10:28:04Z
dc.date.issued2019
dc.identifier.isbn978-82-8406-020-0
dc.identifier.urihttps://hdl.handle.net/11250/2980345
dc.language.isoeng
dc.publisherNorwegian Institute of Public Health / Folkehelseinstituttet
dc.relation.urihttps://www.fhi.no/globalassets/dokumenterfiler/rapporter/2019/prosigna-gene-signature-to-assess-expected-benefit-from-chemotherapy-in-breast-cancer-rapport-2019-v2.pdf
dc.titleProsigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission
dc.title.alternativeProsigna genprofiltest for å vurdere forventet nytte av kjemoterapi ved brystkreft. Vurdering av innsendt informasjon
dc.typeResearch report
dc.description.versionpublishedVersion
dc.source.pagenumber70
dc.identifier.cristin2003211
cristin.ispublishedtrue
cristin.fulltextoriginal


Files in this item

Thumbnail
Name:
Fagerlund-2019-Pro.pdf
Size:
2.183Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record